Rationale and Design of CASPER

Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure

Paul Hauptman, Susan J. Pressler, Jonathan Sackner-Bernstein, Paul Ordronneau, James E. Udelson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7-8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.

Original languageEnglish (US)
Pages (from-to)60-66
Number of pages7
JournalAmerican Journal of Cardiology
Volume98
Issue number7 SUPPL.
DOIs
StatePublished - Oct 25 2006
Externally publishedYes

Fingerprint

Compliance
Heart Failure
Quality of Life
Medicare
Patient Satisfaction
carvedilol
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and Design of CASPER : Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure. / Hauptman, Paul; Pressler, Susan J.; Sackner-Bernstein, Jonathan; Ordronneau, Paul; Udelson, James E.

In: American Journal of Cardiology, Vol. 98, No. 7 SUPPL., 25.10.2006, p. 60-66.

Research output: Contribution to journalArticle

Hauptman, Paul ; Pressler, Susan J. ; Sackner-Bernstein, Jonathan ; Ordronneau, Paul ; Udelson, James E. / Rationale and Design of CASPER : Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 7 SUPPL. pp. 60-66.
@article{5289ddf2a0f2478eaf32442f11ea05b9,
title = "Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure",
abstract = "Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7-8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.",
author = "Paul Hauptman and Pressler, {Susan J.} and Jonathan Sackner-Bernstein and Paul Ordronneau and Udelson, {James E.}",
year = "2006",
month = "10",
day = "25",
doi = "10.1016/j.amjcard.2006.08.004",
language = "English (US)",
volume = "98",
pages = "60--66",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Rationale and Design of CASPER

T2 - Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure

AU - Hauptman, Paul

AU - Pressler, Susan J.

AU - Sackner-Bernstein, Jonathan

AU - Ordronneau, Paul

AU - Udelson, James E.

PY - 2006/10/25

Y1 - 2006/10/25

N2 - Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7-8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.

AB - Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7-8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.

UR - http://www.scopus.com/inward/record.url?scp=33749118012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749118012&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.08.004

DO - 10.1016/j.amjcard.2006.08.004

M3 - Article

VL - 98

SP - 60

EP - 66

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7 SUPPL.

ER -